NCT01878669Active, not recruitingPhase 3
Effects of N-acetyl Cysteine During Percutaneous Coronary Intervention
Effects of N-acetyl Cysteine on Periprocedural Myocardial Infarction and Major Cardiac and Cerebral Events in Patients Undergoing Percutaneous Coronary Intervention
Source: ClinicalTrials.gov · Last updated 20 May 2025
Brief summary (registry, in English)
The aim of this study is to evaluate the effects of N-acetyl cysteine on periprocedural myocardial infarction and major cardiac and cerebral events in patients undergoing percutaneous coronary intervention and who have moderate to high risk for contrast induced nephropathy.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 390 (estimated)
- First submitted
- 26 Mar 2013
- Start date
- Jan 2013
- Primary completion date
- Sept 2017
- Lead sponsor
- Suleyman Demirel University
- Diseases
- Coronary artery disease
- NCT number
- NCT01878669
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 390
- From Jan 2013 to the primary completion date, Sept 2017
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of corticosteroids
- Blood pressure of \>180/100mmHg despite anti-hypertensive therapy
Other illness
- Infection
- Renal failure requiring dialysis
- Hepatic failure
- History allergy for NAC
- History of Asthma
- Malignancy
Other
- Primary percutaneous coronary intervention
- Low risk for contrast induced nephropathy (Mehran Score \< 5)
- Use of nephrotoxic agents (NSAIDs, aminoglycosides,recent contrast injection...)
- Pregnancy, Lactation
- Chronic nitrate usage
- Leukocytosis,Thrombocytosis,Anemia
Who the study is looking for
- Patients \> 18 years old undergoing percutaneous coronary intervention and who have moderate to high risk for contrast induced nephropathy (Mehran Score ≥ 5)
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Suleyman Demirel University Coordinator of this site? Confirm its status | Isparta | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.